Posted in | News | Materials Analysis

Wiley releases Mass Spectra of Designer Drugs 2024 to accelerate forensics analysis of fentanyls, cannabinoids, and more

Wiley, one of the world’s largest publishers and a global leader in research and learning, today announced the 2024 release of the Mass Spectra of Designer Drugs.

Wiley releases Mass Spectra of Designer Drugs 2024 to accelerate forensics analysis of fentanyls, cannabinoids, and more

Image Credit: Wiley

This indispensable spectral database serves as a cornerstone for forensic laboratories worldwide, enabling swift identification of illicit substances. Sourced from both legal and underground literature, it provides access to the latest novel psychoactive substances (NPS) like variants of fentanyl, xylazine, various opioids, synthetic cannabinoids, and more.

This annually refreshed database provides access to 35,094 mass spectra representing 26,712 unique chemical entities, along with detailed information and chemical structures. This year’s update introduces over 850 new mass spectra and over 500 new, unique compounds in major categories of interest.

“With newly synthesized NPS drugs hitting the streets daily, it’s critical for forensic labs to have access to the most recent data to keep up. For labs using mass spec to identify drugs, this is an essential resource,” said Graeme Whitley, Director, Data Science Solutions at Wiley.

Mass Spectra of Designer Drugs is compatible with most major mass spectrometry data systems. It is now also available as a KnowItAll subscription for use with Wiley's KnowItAll spectral analysis software, with innovative tools to assist in the identification of novel compounds using structure/fragment relationships.

Learn more at Wiley Science Solutions
https://sciencesolutions.wiley.com/solutions/technique/gc-ms/mass-spectra-of-designer-drugs/

About Wiley

Wiley (NYSE: WLY) is one of the world’s largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We empower knowledge-seekers to transform today’s biggest obstacles into tomorrow’s brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on FacebookTwitter, LinkedIn and Instagram.

Media Contacts: Wiley / [email protected]

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    John Wiley and Sons - Scientific Publishers. (2024, April 19). Wiley releases Mass Spectra of Designer Drugs 2024 to accelerate forensics analysis of fentanyls, cannabinoids, and more. AZoM. Retrieved on July 12, 2024 from https://www.azom.com/news.aspx?newsID=62875.

  • MLA

    John Wiley and Sons - Scientific Publishers. "Wiley releases Mass Spectra of Designer Drugs 2024 to accelerate forensics analysis of fentanyls, cannabinoids, and more". AZoM. 12 July 2024. <https://www.azom.com/news.aspx?newsID=62875>.

  • Chicago

    John Wiley and Sons - Scientific Publishers. "Wiley releases Mass Spectra of Designer Drugs 2024 to accelerate forensics analysis of fentanyls, cannabinoids, and more". AZoM. https://www.azom.com/news.aspx?newsID=62875. (accessed July 12, 2024).

  • Harvard

    John Wiley and Sons - Scientific Publishers. 2024. Wiley releases Mass Spectra of Designer Drugs 2024 to accelerate forensics analysis of fentanyls, cannabinoids, and more. AZoM, viewed 12 July 2024, https://www.azom.com/news.aspx?newsID=62875.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.